SOCS-1 is an inducible SH2-containing inhibitor of Jak kinases and as such can potently suppress cytokine signaling. SOCS-1 de®cient mice die within the ®rst three weeks of life from a myeloproliferative disorder driven by excessive interferon signaling. We report here that SOCS-1 inhibits proliferation signals induced by a variety of oncogenes active within the hematopoietic system. Ectopic expression of SOCS-1 abolished proliferation mediated by a constitutively active form of the KIT receptor, TEL-JAK2, and v-ABL, and reduced metastasis from BCR-ABL transformed cells. SOCS-1, however, did not interfere with v-SRC or RASV12 mediated cellular transformation. A mutant form of SOCS-1 unable to bind through its SH2 domain to tyrosine phosphorylated proteins could still inhibit KIT, but not TEL-JAK2, indicating multiple mechanisms for SOCS-1-mediated tumor suppression. We show that the steady state levels of TEL-JAK2 and to a greater extent v-ABL are diminished in the presence of SOCS-1. Lastly, we show that SOCS-1 7/7 ®broblasts are more sensitive than wild type ®broblasts to either spontaneous or oncogene-induced transformation. These data suggest that loss-of-function of SOCS-1 may collaborate with a variety of hematopoietic oncogenes to facilitate tumor progression.
Introduction
Cytokines have widespread function during all stages of hematopoietic development. Cytokines regulate decisions of lineage commitment, cell survival, and proliferation. Their function is mediated by transmembrane receptors that transduce intracellular signals through the engagement and activation of cytoplasmic eectors molecules. The duration and intensity of cytokine-induced signals are regulated by protein tyrosine phosphatases (Frearson and Alexander, 1997; Siminovitch and Neel, 1998) , phosphatidyl inositol lipid phosphatases (Krystal, 2000; Rohrschneider et al., 2000) , and by the induction the SOCS-family of JAK kinase pseudosubstrate inhibitors (Endo et al., 1997; Naka et al., 1997 Naka et al., , 1999 Starr and Hilton, 1999; Starr et al., 1997; Yasukawa et al., 2000) .
SOCS-1 binds directly to the conserved regulatory tyrosine in the activation loop of the JAK2 kinase (JH1) domain through its SH2 domain and inhibits JAK kinase activity presumably through occlusion of the substrate binding site Yasukawa et al., 1999) . SOCS-1 also interferes with signaling through the KIT receptor tyrosine kinase, though in a manner which does not suppress its catalytic activity (De Sepulveda et al., 1999) . The SOCS-1 SH2 domain binds to KIT at a site outside of the activation loop contained within the non-catalytic substrate-binding region known as the kinase insert (Chan and Rottapel, unpublished data) . The capacity of SOCS-1 to suppress KIT activity may be related to its ability to bind to and destabilize the guanine nucleotide exchange factor VAV-1 (De , an important KIT substrate. This observation, together with the recent ®nding that SOCS-1 forms a physical complex with components of the VCB E3 ubiquitin ligase, Elongin B and C (Kamura et al., 1998; Zhang et al., 1999) through its C-terminal SOCS Box, has led to a model whereby SOCS-1 functions as an adapter molecule to recruit target proteins such as VAV for ubiquitination and subsequent degradation De Sepulveda et al., 2000; Tyers and Rottapel, 1999) .
The process of cell transformation includes both the activation of oncogenes and the suppression of inhibitory signals that normally operate to regulate the duration and intensity of signals. As a negative regulator of cytokine signaling, SOCS-1 is a candidate gene for inactivating mutations that will favor the development of hematopoietic malignancies. SOCS-1 de®cient mice die within 3 weeks after birth from a myeloproliferative disorder resulting from unbridled IFN-g and TNF-a signaling Starr et al., 1998; Alexander et al., 1999; Marine et al., 1999b; Morita et al., 2000) . Deletion of SOCS-3, the most similar SOCS-family member to SOCS-1, results in polycythemia, a premalignant form of erythroid leukemia (Marine et al., 1999a) . This observation demonstrates that SOCS-3 is a critical regulator of normal erythropoiesis and that loss-of-function mutations in a SOCS-family gene leads to disordered proliferation.
We have recently observed that SOCS-1 could inhibit the oncogenic form of VAV . We have now addressed the question of whether SOCS-1 could inhibit cell proliferation induced by oncogenic forms of other known SOCS-1 interacting proteins. We show here that SOCS-1 suppresses the growth of cells transformed either by an oncogenic form of the KIT receptor or by the TEL-JAK2 fusion protein. The mechanism of inhibition by which SOCS-1 inhibits KIT and TEL-JAK2 is distinct since the SH2 domain of SOCS-1 is required for inhibition of TEL-JAK2 whereas it is dispensable for inhibition of KIT mediated transformation. In addition, since SOCS-1 can down-regulate several signaling pathways that promote cell proliferation, we have also tested whether SOCS-1 could aect other oncogenes beyond those that are known to interact with SOCS-1. We found that SOCS-1 inhibited the proliferation of v-ABL, p210 BCR-ABL or 70Z/3 CBL transformed cells, but not cells transformed by v-SRC or activated RAS.
Results

SOCS-1 inhibits the proliferation of KIT transformed cells
We have previously shown that SOCS-1 suppresses the proliferative signals transduced by the wild type form of the KIT receptor tyrosine kinase (De Sepulveda et al., 1999) . As shown in Figure 1a , expression of SOCS-1 in the KIT ligand-dependent cell line EML, blocks its proliferation. To test whether SOCS-1 could also inhibit the proliferative signal transduced by an oncogenic form of KIT, we used the BaF/3-KitD27 cell line that expresses a mutant KIT protein carrying a 9 amino-acid deletion in the juxtamembrane region (Dubreuil et al., submitted) . KitD27 is constitutively activated and BaF/3-KitD27 cells proliferate in the absence of IL-3. We used the pMiev bicistronic retrovirus to infect BaF/3-KitD27 with either the control vector expressing GFP alone or with a vector expressing both SOCS-1 and GFP (pMiev-SOCS-1). BaF/3-KitD27 cells were infected, sorted for GFP expression and the proliferation of the cells was assessed. As illustrated in Figure 1 , the expression of SOCS-1 suppressed the proliferation of BaF/3-KitD27 cells (Figure 1b) .
Inhibition by SOCS-1 is not dependent on the KIT/ SOCS-1 physical interaction
The SOCS-1 protein can be divided into three distinct regions, each of which are involved in protein-protein interactions . We have previously shown that the N-terminal sequences contain classical diproline motifs involved in the binding of SH3-containing molecules including ITK, p85 and GRB2 (De Sepulveda et al., 1999) . The central SH2 domain is responsible for binding to both tyrosine phosphorylated proteins such as JAKs, KIT, and TEC and to the non-phosphorylated N-terminus of VAV Endo et al., 1997; Ohya et al., 1997) . Lastly, the conserved C-terminal SOCS-Box binds to Elongin C (Kamura et al., 1998; Zhang et al., 1999) . To characterize which regions of SOCS-1 are required to inhibit KIT-mediated mitogenesis, proliferation assays were carried out on EML-C1 and BaF/3-KitD27 cells expressing either wild type, delta N (DN), delta C (DC) or an SH2 mutant SOCS-1 protein. SOCS-1DN has a deletion of the N-terminal 63 amino acids while the entire SOCS-Box is deleted in SOCS-1DC. SOCS-1 R105K carries a point mutation in the phosphotyrosine binding pocket of the SOCS-1 SH2 domain that impairs the speci®c binding to tyrosine phosphorylated KIT or JAK2 (De Sepulveda et al., 1999) . Expression of both SOCS-1DN and SOCS-1DC constructs were systematically lower than wild type SOCS-1 and SOCS-1 R105K (Figure 1c,d ) as determined by Western blotting. Both SOCS-1 R105K and SOCS-1DC were as ecient as wild type SOCS-1 in repressing KIT dependent proliferative signals (Figure 1c,d ). This indicates that neither the SOCS-Box nor the phosphotyrosine binding property of the SH2 domain are required on their own for the inhibition. Considering the degree of partial inhibition of KIT signaling by SOCS-1DN and its low expression (Figure 1d ) we concluded that the N-terminus of SOCS-1 is also dispensable for the inhibition of KIT-mediated cell proliferation. Therefore, none of the domains of SOCS-1 on their own are required for inhibition of KIT. This result suggests that the SH2 domain mediates this inhibition independently of its phosphotyrosine-binding function. In addition, since the R105K mutant does not bind to KIT, SOCS-1 inhibition of KIT-mediated proliferation occurs presumably through interactions of SOCS-1 with signaling molecules acting downstream of KIT such as VAV .
SOCS-1 inhibits the proliferation of cells transformed by oncogenes involved in hematopoietic malignancies
We next investigated whether SOCS-1 could reduce the proliferation of cells transformed by other oncogenes, which participate in the transformation of hematopoietic cells. We tested the eect of constitutive expression of SOCS-1 on the proliferation of Ba/F3 cells transformed by the TEL-JAK2, BCR-ABL, or v-ABL oncogenes and the 70Z/3 cell line transformed by the CBL oncogene. TEL-JAK2 is a fusion protein resulting
The tumor suppressor activity of SOCS-1 R Rottapel et al from the t(9;12)(p24;p13) chromosomal translocation that brings the TEL transcription factor in juxtaposition with JAK2 tyrosine kinase. This translocation was found originally in patients with chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) (Lacronique et al., 1997; Peeters et al., 1997) . The fusion event renders the TEL-JAK2 protein tyrosine kinase constitutively activate (Ho et al., 1999; Lacronique et al., 1997; Schwaller et al., 1998) . Constitutive expression of SOCS-1 blocked the proliferation of cells transformed with TEL-JAK2 (Figure 2a) . Indeed, TEL-JAK2 transformed Ba/F3 cells expressing SOCS-1 died within 48 h as seen by staining with the vital dye 7-AAD and AnnexinV (Figure 2c ). SOCS-1 binds to JAK2 through its SH2 domain and a peptide sequence that includes the phosphorylated Y1007 residue in the activation loop of JAK2 catalytic domain (Yasukawa et al., 1999) . A point mutation at residue R105 in the SOCS-1 SH2 domain has been shown to impair SOCS-1 mediated inhibition of JAK kinases . As illustrated in Figure 2b , the inhibition exerted by SOCS-1 on the proliferation of TEL-JAK2 is greatly reduced by the R105K mutation. Accordingly, staining of the cells with 7AAD or AnnexinV revealed that cells expressing the R105K mutation were viable ( Figure  2c ). Therefore, while the R105 residue in SOCS-1 was dispensable for inhibition of KIT-mediated proliferation, it is required for inhibition of cell-proliferation mediated by TEL-JAK2 oncoprotein. The fact that cells expressing the R105K mutation grew somewhat more slowly than control cells probably re¯ects the fact that the R105K mutation is not a complete loss-offunction mutation .
The Philadelphia translocation is the most common genetic defect associated with CML patients (Mauro and Druker, 2001 ). This translocation creates a fusion protein between BCR and the ABL tyrosine kinase. Like TEL-JAK2, the fusion event renders the ABL protein tyrosine kinase constitutively active. A second oncogenic version of ABL, v-ABL, results from retroviral transduction and causes a pre-B cell leukemia in infected mice. The proliferation of Ba/F3 BCR-ABL was diminished but not abolished in cells expressing SOCS-1 compared to Miev infected cells (Figure 3a) . In contrast, cells transformed by v-ABL CBL is an important negative regulator of protein tyrosine kinases in cells of hematopoietic origin (Lupher et al., 1999) . CBL is a large scaold protein which assembles a variety of signal transducing proteins into close proximity to UBC H7, a ring-®nger dependent E-3 ligase so as to facilitate their ubiquitination and subsequent destruction (Joazeiro et al., 1999; Levkowitz et al., 1999; Zheng et al., 2000) . One of several transforming versions of CBL was identi®ed in a pre-B leukemic cell line 70Z/3 and carries a 17-amino acid deletion in a linker region between the CBL SH2 domain and the ring ®nger domain (Blake et al., 1991) . This mutation results in the dysregulated activity of protein tyrosine kinases leading to factor independent growth (Andoniou et al., 1994) . Ectopic expression of SOCS-1 in 70Z/3 cells inhibited their growth ( Figure  3c ).
To further investigate whether SOCS-1 is a general inhibitor of cell proliferation we tested the capacity of SOCS-1 to interfere with the growth of NIH3T3 ®broblasts transformed with the v-SRC and RAS V12 oncogenes. Expression of SOCS-1 had no eect on the growth of NIH3T3 transformed by either v-SRC or RASV12 (Figure 3d ,e). Accordingly, while SOCS-1 potently suppressed VAV-induced foci formation , SOCS-1 did not reduce the transformation of v-SRC or RAS V12 as measured in a 3T3 foci assay (not shown).
SOCS-1 abolished TEL-JAK2 mediated Stat phosphorylation and increased p38 activation
We next determined the activation status of signaling molecules lying downstream of the JAK, PI3K and MAP-kinase pathways to investigate the mechanism by which SOCS-1 suppresses BCR-ABL and TEL-JAK2 transformed cells. Phospho-speci®c antibodies that recognize the activated forms of STATS, AKT, ERK1/2 and p38 HOG were used to probe lysates from BCR-ABL and TEL-JAK2 transformed cells expressing SOCS-1.
In both TEL-JAK2 and BCR-ABL Ba/F3 cells, phosphorylation levels of AKT (Figure 4a , top panels) and of ERK1/2 (not shown) were similar in cells transfected with either SOCS-1 or the mock vector, suggesting that the PI3K/AKT and the RAS/MAP kinase pathways are not a target of SOCS-1 inhibition. The activation of p38 HOG was increased in both TEL-JAK2 and BCR-ABL Ba/F3 cells in the presence of SOCS-1 (Figure 4a , lower panels, lanes 1 ± 4). By contrast, STAT1, STAT3 and STAT5 phosphorylation were completely abolished by SOCS-1 expression in TEL-JAK2 cells (Figure 4b ). STAT5 phosphorylation was diminished in BCR-ABL transformed cells coexpressing SOCS-1 (Figure 4b , lanes 1 and 2). We then assessed the state of TEL-JAK2 phosphorylation as a surrogate marker of its kinase activity in cells expressing SOCS-1. In Figure 4c we observed that the phosphorylation of TEL-JAK2 was abolished in cells expressing SOCS-1. We also noted that coexpression of TEL-JAK2 with SOCS-1 reduced the expression of TEL-JAK2 (Figure 4c ). To further examine this eect, we coexpressed tagged versions of TEL-JAK2 and SOCS-1 in COS7 cells and observed a reduction in TEL-JAK2 protein expression (Figure 5a ), abolishment of its autophosphorylation ( Figure 5b ) and its capacity to phosphorylate endogenous STAT3 (Figure 5c ). The reduction in the kinase activity of TEL-JAK2 was only partially attributable to the reduction in TEL-JAK2 expression suggesting that SOCS-1 suppresses the oncogenic potential of TEL-JAK2 by both pseudosubstrate inhibition and by diminishing its steady state level of expression. In contrast to these eects on TEL-JAK2, SOCS-1 neither altered phosphotyrosyl content of BCR-ABL or diminished its expression (Figure 4d ). 
SOCS-1 deficient fibroblasts exhibit transformed characteristics and potentiate oncogene-induced transformation
We have shown that constitutive expression of SOCS1 can attenuate cellular transformation by various oncogenes. We tested whether SOCS-1 might function as a tumor suppressor protein by analysing the susceptibility of SOCS-1 de®cient cells to undergo cellular transformation. Populations of embryonic ®broblasts were derived from either wild type (R4 and R8 cell lines) or SOCS17/7 (R7 and R10 cell lines) day 15 embryos. The R4 and R10 cell lines were analysed at passage number 25 ± 30, while R7 and R8 were analysed at passage number 45 ± 50. We tested the capacity of these cell lines to demonstrate contact inhibition at con¯uence or to grow in low serum. Both SOCS-1 de®cient cell lines formed foci 7 ± 10 days after reaching con¯uence, while the primary embryonic ®broblast lines derived from normal mice properly BCR-ABL infected with pMiev or pMiev-SOCS-1 retroviruses were lysed following 3 h of serum starvation. Whole cell lysates were ®rst probed for the indicated phospho-proteins to detect the activated species, and subsequently reprobed with control antibodies that recognise both phosphorylated and non-phosphorylated species. Cells stimulated with IL-3 were used as positive controls in (a). In (c) and (d) lysates were immunoprecipitated either with anti-myc 9E10 or anti-ABL antibodies to isolate myc-tagged TEL-JAK2 and BCR-ABL proteins respectively, and the immunocomplexes were probed with antiphosphotyrosine antibody (4G10). Expression of TEL-JAK2 and BCR-ABL in cells that overexpress SOCS-1 was determined by Western blot analysis Figure 5 Inhibition of TEL-JAK2 expression and tyrosine phosphorylation in COS7 cells. COS7 cells were transfected with plasmids driving the expression of HA-tagged TEL-JAK2 and SOCS-1 proteins. TEL-JAK2 expression was analysed in total cell lysates (a) or TEL-JAK2 immunoprecipitates (bottom of b and c). TEL-JAK2 tyrosine phosphorylation was determined by phosphotyrosine blotting of TEL-JAK2 immune complexes in the presence or absence of SOCS-1 (b). TEL-JAK2 induced tyrosine phosphorylation of STAT3 was analysed in total cell lysates using a phospho-speci®c STAT3 antibody (c top), the membrane was reprobed to control for STAT3 expression (c middle), and for TEL-JAK2 and SOCS-1 expression (c bottom)
The tumor suppressor activity of SOCS-1maintained monolayers (Figure 7a ). This phenotype of the SOCS17/7 cells could be largely reverted by reintroduction of SOCS-1 by retroviral mediated gene transfer, indicating that the loss of contact inhibition was principally due to the deletion of the SOCS-1 gene (Figure 7b) . In a second set of experiments, the ®broblast cell lines were seeded at low density and grown in low serum (0.5% FBS). Both SOCS-17/7 cell lines grew eectively in low serum while the wildtype cells stopped growing (Figure 7c ) and showed signs of apoptosis (not shown). The properties of excessive foci formation in serum and defective inhibition of cell growth at con¯uence of the SOCS-1 de®cient ®broblasts suggest that SOCS-1 may be a candidate tumor suppressor protein.
We next tested whether the SOCS-17/7 cells were more sensitive to oncogene-induced transformation using foci assays. R4, R7, R8 and R10 ®broblasts were transfected with the oncogenes TEL-JAK2, KITD27 and Cbl 70Z3. As depicted in Figure 8 , TEL-JAK2, 70Z3/Cbl and KIT D27 all demonstrated increased foci-formation potential in SOCS-1 de®cient ®broblasts compared to normal ®broblasts. During the short period of this assay (10 days as opposed to 18 days in Figure 7 ) only KITD27 induced foci in the wild type cell line (R4). Similarly, the level of spontaneous foci observed for R10 was reduced compared to the results observed in Figure 7 . These data show that SOCS-1 de®cient ®broblasts potentiate the oncogenic potential of TEL-JAK2, 70Z3/Cbl and KIT D27.
Discussion
SOCS-1 is a potent inhibitor of the JAK/STAT pathway and of the hematopoietic exchange factor VAV. In a ®rst approach to evaluate SOCS-1 as a potential antagonist of hematopoietic tumorigenesis, we have tested whether SOCS-1 could interfere with the mitogenic signals rendered by several hematopoietic oncogenes. We show here that SOCS-1 can suppress proliferative signals initiated by oncogenic forms of KIT, JAK2, and ABL. The tumor suppressive eect of SOCS-1 is speci®c as its overexpression cannot interfere with either RAS or SRC dependent ®broblast transformation.
Ectopic expression of SOCS-1 blocks the constitutive tyrosine phosphorylation of TEL-JAK2 and hence its capacity to phosphorylate downstream targets such as STAT1 and STAT5 necessary for cellular transformation (Schwaller et al., 2000) . In addition to functioning as a pseudosubstrate inhibitor of TEL-JAK2, we observed that its steady state expression levels of TEL-JAK were markedly decreased in the presence of SOCS-1. This observation is similar to our previous report that SOCS-1 destabilizes the steady state expression of VAV and onco-VAV through a process of ubiquitination and proteasomal degradation . Three recent reports describe the promotion of TEL-JAK2 ubiquitination and degradation by SOCS-1 (Frantsve et al., 2001; Kamizono et al., 2001; Monni et al., 2001) . Collectively, these data support the hypothesis SOCS-1 links target proteins such as VAV or TEL-JAK to the machinery of ubiquitination and degradation (Tyers and Rottapel, 1999) .
We observed that v-ABL and BCR-ABL demonstrate a dierential sensitivity to SOCS-1 mediated growth suppression. SOCS-1 potently blocked proliferation of v-ABL transformed cells whereas BCR-ABL transformed cells could still grow albeit at a slower rate in the presence of SOCS-1. SOCS-1 transfected BCR-ABL cells still formed local tumors in nude mice but they lost their metastatic potential. These dierences c Tumors were apparent in the liver, spleen and lungs may re¯ect dierences in the signal transduction pathways that are activated by these two related oncogenes. v-ABL physically interacts with JAK-1 in vivo and a dominant negative form of JAK-1 reduces v-ABL-induced STAT activation and tumor formation suggesting that JAK-1 is likely a major target of v-ABL (Danial et al., 1998) . BCR-ABL also appears to activate a variety of STAT proteins but does so independently of JAK activation (Danial et al., 1998) . We observed that STAT5 was constitutively activated in both v-ABL and BCR-ABL. However, STAT5 phosphorylation was abolished in v-ABL cells expressing SOCS-1, whereas the phosphorylation of STAT5 was diminished but still present in BCR-ABL transformed cells expressing SOCS-1. The dierential action of SOCS-1 on v-ABL and BCR-ABL may re¯ect the dierential eect of SOCS-1 on the steady state expression level of these two oncogenic forms of ABL. The expression level of BCR-Abl was unaected by SOCS-1 while v-ABL protein was, to the level of detection, absent in the presence in SOCS-1. We are currently testing whether SOCS-1 induces the ubiquitin-dependent destruction of v-ABL as has been described for VAV-1 (De and whether the suppression of v-ABL requires direct physical interaction between the two proteins. SOCS-1 also inhibits TEL-JAK2 and oncogenic forms of KIT through dierent mechanisms. SOCS-1 suppresses TEL-JAK2 at a proximal point in its signaling cascade by inhibiting the intrinsic catalytic Figure 7 SOCS1 7/7 ®broblasts demonstrate characteristics of a transformed phenotype. (a) Loss of contact-inhibition in +/+ and 7/7 embryonic ®broblasts. Fibroblast cell lines derived from wild type (R4 and R8) or SOCS1 7/7 (R7 and R10) embryos were grown to con¯uence and stained with GIEMSA after 15 ± 18 days of culture. Two plates of each cell type are shown. R4 and R10 cell lines were derived from littermates and were used at passage number 25, while R7 and R10 were used at passage number 45. (b) Suppression of SOCS-1 de®cient ®broblast foci formation by ectopic expression of SOCS-1. The parental cell line R10 was infected with a pMIEV SOCS1 retrovirus. The parental (R10) and the population of stably transfected cells (R10/SOCS1) were grown to con¯uence and stained with GIEMSA. (c) SOCS-1 de®cient ®broblasts grow in low serum. R4, R7, R8 and R10 were plated in 6-well plates in triplicate and grown in 0.5% FBS. Absolute numbers of viable cells were counted at 4 days and graphed
The tumor suppressor activity of SOCS-1 R Rottapel et al activity of the fusion kinase and by attenuation of its steady state expression. We have shown that SOCS-1 does not inhibit the phosphorylation status of KIT nor its downsteam eector molecules (De Sepulveda et al., 1999) . We have further demonstrated that the SOCS-1 R105K mutant, which is unable to bind to tyrosine phosphorylated proteins and no longer can inhibit TEL-JAK2, still potently interferes with KIT oncogenesis (De Sepulveda et al., 1999) . Although JAK2 has been shown to be phosphorylated in response to KIT activation (Weiler et al., 1996) it is unlikely to be a necessary target of SOCS-1 suppression since the SOCS-1 R105K mutant does not inhibit wild type JAK2 . These observations strongly suggest that suppression of KIT signaling is due to the inhibition of targets other than JAK2. We propose that SOCS-1 inhibition occurs downstream of KIT through its interactions with required eectors of KIT-mediated transformation such as the VAV guanine nucleotide exchange factor. We have observed that overexpression of SOCS-1 had no eect on signaling through the AKT, ERK, or JNK pathways. The inability of SOCS-1 to suppress RAS V12 or v-SRC transformed cells is consistent with our observation that SOCS-1 does not inhibit activation of the ERK MAP-kinase pathway (Morita et al., 2000) . We found however, that ectopic expression of SOCS-1 paradoxically stimulated phosphorylation of p38 HOG in Ba/F3 cells. A recent study showed that SOCS-1 increased and sustained the activation of p38 HOG in response to TNFa in murine ®broblasts, a response that was impaired in SOCS-1 de®cient cells (Morita et al., 2000) . Although the pathway by which SOCS-1 couples to p38 HOG is unknown, activation of p38 HOG may be one mechanism of how SOCS-1 arrests cells transiting the cell cycle (Alderton et al., 2001; Bulavin et al., 2001) .
Our data show that high expression of SOCS-1 can block the transforming activity of several hematopoietic-speci®c oncogenes and that deletion of SOCS-1 in cells may contribute to cellular transformation. These observations are consistent with the notion that SOCS-1 might function as a tumor-suppressor gene. In support of this idea, two recent studies report that the SOCS-1 locus is silenced by hypermethylation in two-thirds human of hepatocellular carcinomas (Nagai et al., 2001; Yoshikawa et al., 2001) . The JAK/STAT pathway is constitutively activated in hepatocellular carcinoma cell lines in which the SOCS-1 locus is hypermethylated suggesting that the normal regulation the JAK/STAT pathway is lost in these lines. Forced SOCS-1 expression or the application of a JAK-2 speci®c inhibitor suppressed the growth of these cell lines. Silencing of the SOCS-1 locus on human chromosome 16 may be a necessary step during tumor progression in malignancies such as multiple myeloma where cytokine activation participate in pathogenesis (Kawano et al., 1988) . We are currently testing whether primary SOCS-1 heterozygote ®broblasts are prone to tumor formation with loss of heterozygosity of the SOCS-1 locus as an additional measure of its tumor suppressive potential. Murine genetic models which might demonstrate SOCS-1 as a tumor suppressor gene are lacking as mice de®cient in SOCS-1 die within the ®rst 3 weeks after birth and hence do not survive long enough for tumors to arise. However, loss of function mutations in several SOCS-Box containing proteins predispose to malignant or pre-malignant states. Mice de®cient in SOCS-3, the most similar protein to SOCS-1, develop polycythemia, a pre-leukemic myeloproliferative disorder. Mutations in the SOCS-box containing tumor suppressor gene product VHL is associated with tumors of the central nervous system, kidney, retina, pancreas and adrenal gland. VHL mutations leads to the inappropriate accumulation of hypoxia inducible factor-1, HIF, a transcription factor which controls angiogenesis, an important step during tumor metastasis. Therefore, SOCS-Box containing proteins such as SOCS-1 may function as a tumor suppressor gene by regulating either the activity or the abundance of proto-oncogenes.
Materials and methods
Cell lines
Ba/F3-KitD27, Ba/F3-TEL-JAK2 (Ho et al., 1999) and Ba/ F3-BCR-ABL cells were derived from the IL-3 dependent Ba/ F3 cell line. IL-3 independent cell lines were derived by retroviral gene transfer which stably express a constitutively active mutant KIT receptor, TEL-JAK2 or p210 BCR-ABL. The v-ABL transformed pre-B cell line I-8 and 70Z/3 pre-B cell line were obtained from Dr Chris Paige (Ontario Cancer Institute).
Ba/F3 cells were maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum (FCS) and 1% conditioned medium containing IL-3. Ba/F3-KitD27, Ba/F3-TEL-JAK2, Ba/F3-BCR-ABL, I-
KIT∆27
Control KIT∆27 Control Figure 8 Oncogene-induced foci formation in wild type and SOCS1 7/7 ®broblasts. R4 and R10 ®broblasts were transfected with expression plasmids encoding either TEL-JAK2, KIT-D27 or CBL 70Z3, grown to con¯uence, then stained with GIEMSA. An untransfected plate was included in each experiment to determine background foci formation. Cells were plated at the same density as in Figure 7 but they were grown for 10 days instead of 15 ± 18 days to reduce the level of spontaneous foci formation in the control plates 8 and 70Z/3 cells were grown in RPMI and 10% FCS. NIH3T3 ®broblasts transformed by v-SRC or by RAS V12 (Taparowsky et al., 1982) were grown in Dubelco's Modi®ed Essential Medium (DMEM) and 5% FCS. EML-C1 was grown in Iscove's modi®ed Dulbecco's medium (IMDM) supplemented with 20% horse serum and 10% conditioned media from BHK/mKL containing murine KIT-ligand (Tsai et al., 1994) .
Vectors
Retroviral vectors pMiev and pMiev-HA-SOCS-1 and SOCS-1 R105K mutation in the pMT3 vector were previously described (De Sepulveda et al., 1999) . Deletions of SOCS-1 N-terminus (SOCS-1DN) resulting in the deletion of SOCS-1 amino acids 1 ± 63 was generated by PCR and fused to an N-terminal HA-tag in pMT3. SOCS-1 R105K cDNA and SOCS-1DN were then cloned in pMiev. A deletion of SOCS-1 C-terminus (SOCS-1DC) was generated from pMiev-HA-SOCS-1 by deletion of a NotI fragment resulting in the loss of SOCS-1 amino acids 175 ± 212. All SOCS-cDNAs are fused to an N-terminal HA epitope tag.
Generation and analysis of cell lines expressing SOCS-1
The packaging GP+E cell lines stably producing the respective Miev and Miev-HA-SOCS-1 ecotropic retroviruses were previously described (De Sepulveda et al., 1999) . The SOCS-1 mutant cDNAs cloned in the pMiev vector were introduced in the GP+E cell line to derive stably integrated packaging cell lines. Cells growing in suspension (i.e. Ba/F3-KitD27, Ba/F3-TEL-JAK2, Ba/F3-BCR-ABL, I-8, 70Z/3 and EML-C1) were infected by co-culture with the packaging cell line for 24 ± 48 h. v-SRC or RAS V12 transformed ®broblasts were infected using freshly harvested supernatants from the packaging cell lines. Infected cells expressing mRNA transcripts from the integrated retroviral DNA were isolated on the basis of eGFP expression using a¯ow activated cell sorter. Sorted populations of cells were then controlled for expression of wild type or mutant SOCS-1 proteins by Western blotting.
Proliferation assay
pMiev or pMiev-SOCS-1 infected cells were selected on the basis of eGFP expression and seeded at the density of 1610 3 and 5610 3 cells per well in 96-well plates. Each cell sample was seeded in ®ve wells to determine the variability of the results. Cells were labeled for 6 h with 1 mCi of 3 Hthymidine, and were either directly transferred or lysed by a freeze/thaw cycle before being transferred onto glass®ber ®ltermats and the incorporated radioactivity counted. AnnexinV-PE and 7-amino-actinomycin D were used to detect apoptotic and dead cells by¯ow cytometry according to manufacturer's instructions (Pharmingen).
Biochemistry and antibodies
Proteins from whole cell lysates and immunoprecipitates were separated by SDS-polyacrylamide gel, then transferred to Imobilon membranes (Millipore) and blotted with various antibodies as speci®ed below. HRP-conjugated secondary antibodies were detected using the Enhanced Chemiluminescence (ECL) (Amersham-Pharmacia Biotech).
For detection of SOCS-1, STAT proteins, MAP kinases and AKT, cells were lysed in 26 sample buer and lysates were subjected to Western-blot analysis. The anti-HA mouse monoclonal antibody 12CA5 was used to detect SOCS-1 proteins (1/200 dilutions of hybridoma supernatant). Phospho-p44/42 ERK (Thr202, Tyr204), phospho-JNK (Thr183, Tyr185), phospho-p38 (Thr180, Tyr182) and phospho-AKT (Ser473) speci®c antibodies and the respective control antibodies were used according to the manufacturer instructions (New England Biolabs, Inc). Activation-speci®c Stat1 (Frank et al., 1995) , Stat3 (Bonni et al., 1997) and Stat5 antibodies were raised to a phosphopeptide corresponding to the conserved site of tyrosine phosphorylation of each protein. They were utilized as described (Ho et al., 1999) . Detection of phosphorylated myc-tagged-TEL-JAK2 or BCR-ABL were done by lysing cells in ice-cold lysis buer containing 50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, and 2 mM Na 3 V0 4 . Equalized whole cell lysates were mixed for 18 h with anti-myc (mouse monoclonal 9E10) or anti-ABL (Calbiochem) and protein A coupled to agarose beads (Amersham-Pharmacia Biotech) for immunoprecipitation. Western blot analysis with 4G10 (Upstate Biotechnology) was used to detect phosphotyrosyl containing proteins.
Nude mice injections
Balb/c nu/nu mice were injected subcutaneously with two million cells in 0.2 ml of phosphate buer saline (PBS). Mice were checked in the following weeks for signs of tumors at injection sites. Mice were sacri®ced 5 weeks following injection and dissected to examine for signs of metastasis.
Foci and cell proliferation assays
Primary cultures of ®broblasts were derived from day 15 SOCS17/7 and wild type mouse embryos. Single cell suspensions were plated in DMEM with 10% fetal bovine serum and 50 mM b-mercaptoethanol. The monolayer cultures were passaged every 3 ± 4 days for more than 20 passages. Foci assays were done as previously described . 1.5.10 5 Fibroblasts were seeded in 100 mm plates in DMEM and 5% serum and grown for 10 ± 15 days. The cells were then ®xed in 10% formaldehyde and stained with Giemsa. For proliferation in low serum, 5.10 3 cells were seeded in 6-well plates in triplicates and the cells were counted 4 days later using a Coulter cell counter.
